⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 I løbet af de seneste 7 dage 🍎 Fødevarer: 180 I løbet af de seneste 7 dage 🧸 Kanalens produkter: 48 I løbet af de seneste 7 dage 🟢 Overvågning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Seneste hentning: for 24 minutter siden ⚠ LIVE — European Consumer Safety Watch 💊 Medicinsk kanal: 18 I løbet af de seneste 7 dage 🍎 Fødevarer: 180 I løbet af de seneste 7 dage 🧸 Kanalens produkter: 48 I løbet af de seneste 7 dage 🟢 Overvågning: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Seneste hentning: for 24 minutter siden
🛡️ EUSW
🇩🇰
💊

Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)

dabigatran etexilate
Venøs tromboemboli; artroplastik, erstatning
✅ Autoriseret Generisk
Ingen aktive alarmer
Denne medicin har ingen igangværende mangel, sikkerhedsbreve eller tilbagekaldelser.

Hvad det bruges til

Dabigatran etexilate Leon Farma 75 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 110 mg Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Treatment of VTE and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age. Dabigatran etexilate Leon Farma 150 mg Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from birth to less than 18 years of age.

⚠️ Patient sikkerhed

No

⚠️ Vi sammenfatter officielle meddelelser. Vi giver ikke lægelig rådgivning. Ved lægelige eller juridiske beslutninger skal du konsultere den relevante myndighed og en kvalificeret fagperson.